Pfizer Opens 2021 Call for Proposals for Pre-Clinical Collaboration
Pfizer’s Centers for Therapeutic Innovation (CTI) were founded on the belief that our current scientific and global health challenges are too complex for any one player in the healthcare ecosystem to solve alone. CTI seeks to identify potential partners with whom we can collaborate to help enable the translation of novel scientific concepts into therapies with breakthrough potential for patients.
CTI has opened the 2021 call for interested academic institutions and investigators to submit non-confidential proposals, with the goal of advancing the most promising therapeutic targets aligned to Pfizer’s core areas of expertise – Inflammation & Immunology, Internal Medicine, Oncology, and Rare Disease– as well as emerging science areas that explore underlying pathogenic mechanisms across therapeutic indications.
CTI’s collaborative model deploys Pfizer’s R&D capabilities and resources to help advance the next wave of innovation, leveraging the full Pfizer enterprise and network in the broader life science community to transform visionary hypotheses into viable therapeutics.
To learn more about CTI, interest areas, and submission process, please visit www.pfizercti.com. Proposals will be accepted through June 28, 2021.